Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 106 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy	Osimertinib (Tagrisso; AZD9291; osimertinib mesylate)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Pegargiminase in addition to pemetrexed and cisplatin for advanced malignant pleural mesothelioma – first line	Cisplatin (Platinol) , Pegargiminase (ADI-PEG 20) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2018	View \| Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line	Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Pembrolizumab and chemotherapy for resectable nonsmall-cell lung cancer	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line	Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to standard of care chemotherapy for extensive stage small cell lung cancer – first line	Pembrolizumab (Keytruda; MK-3475)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2018	View \| Download
Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download